drugset / Trial / NCT03919253
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial aim to evaluate the efficacy and safety of Pyrotinib in combination with nab-paclitaxel in patients with HER2-positive advanced breast cancer.
Timeline
- Start
- 2019-04-30
- Primary completion
- 2020-04-30
- Completion
- 2022-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |